

Alexandra G Fraga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8152598/publications.pdf>

Version: 2024-02-01

32
papers

1,454
citations

393982

19
h-index

454577

30
g-index

33
all docs

33
docs citations

33
times ranked

2077
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple facets and functions of the toxin mycolactone produced by <i>Mycobacterium ulcerans</i> . , 2022, , 271-290.		0
2	Genetics in the Host- <i>Mycobacterium ulcerans</i> interaction. <i>Immunological Reviews</i> , 2021, 301, 222-241.	2.8	0
3	Genetic variants in human BCL2L1 (BIM) are associated with ulcerative forms of Buruli ulcer. <i>Emerging Microbes and Infections</i> , 2021, 10, 223-225.	3.0	4
4	Individual and clinical variables associated with the risk of Buruli ulcer acquisition: A systematic review and meta-analysis. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008161.	1.3	4
5	Antimicrobial activity of <i>Mycobacteriophage D29 Lysin B</i> during <i>Mycobacterium ulcerans</i> infection. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007113.	1.3	25
6	Increasing the potential of cell-penetrating peptides for cancer therapy using a new pentagonal scaffold. <i>European Journal of Pharmacology</i> , 2019, 860, 172554.	1.7	7
7	K2 Capsule Depolymerase Is Highly Stable, Is Refractory to Resistance, and Protects Larvae and Mice from <i>Acinetobacter baumannii</i> Sepsis. <i>Applied and Environmental Microbiology</i> , 2019, 85, .	1.4	38
8	The Immunology of Buruli Ulcer. , 2019, , 135-158.		3
9	Immune-evasion Strategies of <i>Mycobacteria</i> and Their Implications for the Protective Immune Response. <i>Current Issues in Molecular Biology</i> , 2018, 25, 169-198.	1.0	12
10	Natural based eumelanin nanoparticles functionalization and preliminary evaluation as carrier for gentamicin. <i>Reactive and Functional Polymers</i> , 2017, 114, 38-48.	2.0	16
11	Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against <i>Mycobacterium tuberculosis</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 403-405.	1.0	11
12	Genetic Variation in Autophagy-Related Genes Influences the Risk and Phenotype of Buruli Ulcer. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004671.	1.3	35
13	Clinical Epidemiology of Buruli Ulcer from Benin (2005-2013): Effect of Time-Delay to Diagnosis on Clinical Forms and Severe Phenotypes. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004005.	1.3	23
14	Spontaneous Healing of <i>Mycobacterium ulcerans</i> Lesions in the Guinea Pig Model. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004265.	1.3	18
15	BCG vaccination-induced long-lasting control of <i>Mycobacterium tuberculosis</i> correlates with the accumulation of a novel population of CD4+IL-17+TNF+IL-2+ T cells. <i>Vaccine</i> , 2015, 33, 85-91.	1.7	42
16	Proteomic Analysis of the Action of the <i>Mycobacterium ulcerans</i> Toxin Mycolactone: Targeting Host Cells Cytoskeleton and Collagen. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3066.	1.3	27
17	Phage Therapy Is Effective against Infection by <i>Mycobacterium ulcerans</i> in a Murine Footpad Model. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2183.	1.3	91
18	Corticosteroid-Induced Immunosuppression Ultimately Does Not Compromise the Efficacy of Antibiotherapy in Murine <i>Mycobacterium ulcerans</i> Infection. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1925.	1.3	13

#	ARTICLE	IF	CITATIONS
19	Local and Regional Re-Establishment of Cellular Immunity during Curative Antibiotherapy of Murine <i>Mycobacterium ulcerans</i> Infection. PLoS ONE, 2012, 7, e32740.	1.1	21
20	Cellular Immunity Confers Transient Protection in Experimental Buruli Ulcer following BCG or Mycolactone-Negative <i>Mycobacterium ulcerans</i> Vaccination. PLoS ONE, 2012, 7, e33406.	1.1	38
21	<i>Mycobacterium ulcerans</i> Triggers T-Cell Immunity followed by Local and Regional but Not Systemic Immunosuppression. Infection and Immunity, 2011, 79, 421-430.	1.0	41
22	IFN- γ -Dependent Activation of Macrophages during Experimental Infections by <i>Mycobacterium ulcerans</i> Is Impaired by the Toxin Mycolactone. Journal of Immunology, 2010, 184, 947-955.	0.4	50
23	Response to Treatment in a Prospective Cohort of Patients with Large Ulcerated Lesions Suspected to Be Buruli Ulcer (<i>Mycobacterium ulcerans</i> Disease). PLoS Neglected Tropical Diseases, 2010, 4, e736.	1.3	53
24	Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with <i>Mycobacterium tuberculosis</i> . Journal of Experimental Medicine, 2010, 207, 1609-1616.	4.2	230
25	Fine-Needle Aspiration, an Efficient Sampling Technique for Bacteriological Diagnosis of Nonulcerative Buruli Ulcer. Journal of Clinical Microbiology, 2009, 47, 1700-1704.	1.8	58
26	Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. International Journal of Antimicrobial Agents, 2008, 31, 37-45.	1.1	85
27	New Foci of Buruli Ulcer, Angola and Democratic Republic of Congo. Emerging Infectious Diseases, 2008, 14, 1790-1792.	2.0	17
28	Developments on Drug Delivery Systems for the Treatment of Mycobacterial Infections. Current Topics in Medicinal Chemistry, 2008, 8, 579-591.	1.0	45
29	First Cultivation and Characterization of <i>Mycobacterium ulcerans</i> from the Environment. PLoS Neglected Tropical Diseases, 2008, 2, e178.	1.3	175
30	Mycolactone-Mediated Inhibition of Tumor Necrosis Factor Production by Macrophages Infected with <i>Mycobacterium ulcerans</i> Has Implications for the Control of Infection. Infection and Immunity, 2007, 75, 3979-3988.	1.0	88
31	Evidence for an Intramacrophage Growth Phase of <i>Mycobacterium ulcerans</i> . Infection and Immunity, 2007, 75, 977-987.	1.0	91
32	Infection with <i>Mycobacterium ulcerans</i> Induces Persistent Inflammatory Responses in Mice. Infection and Immunity, 2005, 73, 6299-6310.	1.0	92